Imeik Technology Development Co.,Ltd. Stock price

Equities

300896

CNE100004868

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-02-28 pm EST 5-day change 1st Jan Change
327 CNY +3.27% Intraday chart for Imeik Technology Development Co.,Ltd. +1.05% +11.10%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 * 2.9B 403M Sales 2024 * 4B 555M Capitalization 70.59B 9.81B
Net income 2023 * 1.86B 259M Net income 2024 * 2.54B 352M EV / Sales 2023 * 23 x
Net cash position 2023 * 4.02B 558M Net cash position 2024 * 5.34B 743M EV / Sales 2024 * 16.3 x
P/E ratio 2023 *
37.9 x
P/E ratio 2024 *
27.9 x
Employees 713
Yield 2023 *
1.02%
Yield 2024 *
1.44%
Free-Float 35.33%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd.'s Equity Buyback announced on June 12, 2023, has closed with 1,165,874 shares, representing 0.54% for CNY 399.69 million. CI
QL Biopharmaceutical announced that it has received CNY 200 million in funding from BlueRun Investment Consulting Co., Ltd., Imeik Technology Development Co.,Ltd., China-US Green Fund Management Co., Ltd., Shenzhen Jiayuan Capital Management Co., Ltd., Chengdu Science and Technology Innovation Investment Group Co., Ltd., Shanghai Jincheng Equity Investment Fund Management Co., Ltd. and other investors CI
Imeik Technology Wins Exclusive Rights to Distribute Jeisys’ Aesthetic Equipment in China MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd. Approves Cash Distribution for the First Half of 2023, Payable on 23 October 2023 CI
Imeik Technology Development Co.,Ltd. Proposes Distribution for the First Half of 2023 CI
Imeik Technology Development's Profit Jumps 65.7% in H1 MT
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Imeik Technology Development Co.,Ltd.'s Equity Buyback Plan announced on June 12, 2023. CI
Imeik Technology Development Co.,Ltd. announces an Equity Buyback for CNY 400 million worth of its shares. CI
Imeik Technology Development Co.,Ltd. authorizes a Buyback Plan. CI
Imeik Technology Development Co.,Ltd. Declares 2022 Final Profit Distribution, Payable on 15 May 2023 CI
Imeik Technology Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day+3.27%
1 week+1.05%
1 month+20.72%
3 months+7.38%
6 months-25.43%
Current year+11.10%
More quotes
1 week
311.93
Extreme 311.93
333.50
1 month
274.18
Extreme 274.18
336.13
Current year
267.58
Extreme 267.58
336.13
1 year
263.21
Extreme 263.21
595.08
3 years
263.21
Extreme 263.21
844.44
5 years
172.78
Extreme 172.7778
844.44
10 years
172.78
Extreme 172.7778
844.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 09-12-31
Director of Finance/CFO 46 21-10-31
44 -
Members of the board TitleAgeSince
Director/Board Member 59 21-07-11
Director/Board Member 57 22-11-16
Director/Board Member 60 22-11-16
More insiders
Date Price Change Volume
24-02-29 327 +3.27% 3,923,590
24-02-28 316.6 -0.89% 4,585,439
24-02-27 319.5 +0.16% 3,761,476
24-02-26 319 -3.30% 3,827,684
24-02-23 329.9 +1.94% 3,459,475

End-of-day quote Shenzhen S.E., February 28, 2024

More quotes
Imeik Technology Development Co Ltd is a China-based company mainly engaged in the research and development, production and sales of biomedical materials. The Company focuses on the development and transformation of biomedical materials, and is committed to the development of biomedicine such as recombinant proteins and peptides. The Company has realized the industrialization of injection-type sodium hyaluronate series products and polydioxanone facial implants, and has established a product technology transformation platform for biomedical materials such as medical chitosan and polylactic acid. The Company's self-developed products are mainly aimed at the repair of fold skin on the face and neck. The clinical applications of its products cover medical cosmetology, surgical repair, and treatment of metabolic diseases. The Company mainly conducts its businesses in the China market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
327 CNY
Average target price
456.6 CNY
Spread / Average Target
+39.64%
Consensus
  1. Stock
  2. Equities
  3. Stock Imeik Technology Development Co.,Ltd. - Shenzhen S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW